Search 

Project Tide is commercializing novel respiration measurement technology developed at Tampere University of Technology. The first application of this technology platform is in DIAGNOSIS AND MANAGEMENT OF CHILDHOOD ASTHMA.

Because of the very limited methods for objective lung function measurement in young children their diagnostic procedures for asthma are currently based on qualitative and subjective estimates of the symptoms. Approximately 15 % of all children exhibit symptoms before school age. There have been technological attempts to solve this widely acknowledged problem, but none have been successful so far. Our approach is paradigm changing and will globally affect the course of pediatric asthma diagnosis and management.

Our innovative system enables lung function measurements with practically no need of co-operation from the child. The measurement is done over one 24h period and analysed for signs of asthma in the respiratory flow pattern.

The technology is currently in clinical trial phase with the leading pediatric asthma research group in Finland. The first phase results on asthmatic preschool children are very encouraging and will be published soon.

We are seeking seed funding to establish a company in Q2 / 2014.

Relaxbirth Ltd. is an innovative MedTech company, presenting a unique, (r)evolutionary all-in-one solution for childbirths.

Our user-centered innovation consists of the CE-marked and patented Relaxbirth® birthing support device, method and services. Relaxbirth is culturally independent, suitable for different traditions.

Relaxbirth was awarded the Best European Woman Innovation 2009 and the Red Herring 2012 Top 100 Europe and Global Winner, among others.

A committed management team, currently consisting of shareholders, is backed by an International Business Management Advisory Board.

Our mission is to provide wellbeing and positive experiences in childbirth, globally.

Excellent feedback from Relaxbirth mothers offers a strong PR advantage also for hospitals and private clinics.

To sum up our business mission, our slogan is: Celebrate Life®!

Relaxbirth® improves the childbirth process and experience for mothers and personnel. It allows women in labour to make best use of their own bodies and to maximize their power to give birth.

Physiologically, using Relaxbirth gives more space to the birthing canal and also diminishes muscular resistance for the baby to be born.

Psychologically, the feedback shows that using Relaxbirth gives a feeling of empowerment: it increases the possibilities to choose among different birthing positions, in addition to the feeling of being in control of one’s own labour.

From the maternity hospitals’ point of view, Relaxbirth helps improve customer satisfaction and provides a strategic competitive edge. Relaxbirth is an answer to individual needs in labour. Relaxbirth® may also help reduce costs and overcome many current challenges related to childbirth.

SuperECG has developed the HeartBug, an affordable and reliable ECG device for the consumers.

With the help of the SuperECG HeartBug and an online analysis service anyone can conduct a cardiac assessment that used to always require a visit to a clinic. The heartBug records the heart’s electrical activity for up to 24 hours and the advanced cardiac analysis system produces a report. The extensive report points out possible findings indicating arrhythmia, as well as the effect of physical exercise on cardiac rhythm.

The technology applied in the device and the analysis software has previously been developed by the parent company RemoteA for several years.

Sca Hygiene Healthcare division. Offers medtech incontinence solutions.Global presence in 90 markets. Expansion and growth priority. 

Mike Hallerstrom, Senior Advisor Healthcare.

Scottish Development International (SDI) is a government-funded organisation with a dedicated Life Sciences team which provides access to key Scottish product and service companies, together with expertise from the Scottish clinical and research base.  SDI also works closely with many leading companies who have invested in Scotland as a European location.

Scotland is home to over 140 medical technology companies, ranging from major multinationals to smaller innovative home-grown companies.Scotland's sheer diversity in medtech offers opportunities for cooperation and collaboration.

SEED Capital is the largest early stage venture fund in Denmark. We invest in companies within Medtech and Technologies at the seed or even pre-seed stage from Denmark and southern Sweden. We invest in classic venture companies meaning companies that as a minimum will provide an opportunity for a 10x return on investment. The company should have a highly innovative solution and a scalable business model for entering an attractive market with a number of identified paths to exit.

Because of our strong partnership with the government funded innovation incubator DTU Symbion Innovation we are able to invest €250-750.000 at the early stages of a company’s development, allowing them an opportunity to prove their technology and business.

Depending on capital need, SEED Capital can invest up to €9 million in the following rounds – preferably in syndication with international investors. We take an active advisory role as an investor and will normally take the position of Chairman of the Board in the company until a skilled alternative is identified.